Study Reports 10-Year Outcomes of Focal Therapy for Prostate Cancer

A landmark multicenter study published in European Urology has established focal therapy as a durable first-line treatment for localized, nonmetastatic prostate cancer, providing oncology nurses and clinicians with long-term data previously unavailable.

The study, the largest of its kind, followed 3,477 men across 14 United Kingdom centers for a decade, revealing that cancer-specific mortality was 0.13%. These findings suggest that for well-selected patients, focal ablation can achieve oncological outcomes comparable to radical surgery or radiotherapy while prioritizing the preservation of quality of life.

Addressing quality of life in prostate cancer care

Historically, patients with localized prostate cancer have navigated a difficult choice between active surveillance and radical treatments like robotic prostatectomy or whole-gland radiotherapy. While effective, radical treatments are frequently associated with long-term side effects, including urinary incontinence and erectile dysfunction.

Focal therapy —utilizing High-Intensity Focused Ultrasound (HIFU) or cryotherapy — targets only the tumor, sparing healthy tissue and the nerves and muscles critical for urinary and sexual function. Researchers note that focal therapy leads to a five-fold lower risk of these side effects compared to traditional radical options.

Study design and patient population

The researchers utilized data from two nationally mandated registries: the HIFU Evaluation and Assessment of Treatment (HEAT) and the International Cryotherapy Evaluation (ICE). The cohort included 2,897 men treated with HIFU and 580 treated with cryotherapy between 2004 and 2024.

Notably, this study expanded beyond low-risk populations; 9 in 10 men in the study had intermediate- or high-risk cancer. Specifically, 25% of the cohort had high-risk disease, and 23% had unfavourable-intermediate-risk disease, categories that traditionally mandate aggressive whole-gland intervention.

Key 10-year oncological outcomes

The primary objective of the study was to report long-term cancer control. At the 10-year mark, the results showed:

• Cancer-specific mortality: Only two men out of the 3,477 died from prostate cancer (0.13%).
• Metastasis development: The cumulative incidence of metastases was 3.3%.
• All-cause mortality: 12% of the patients died from any cause within the decade.

When analyzing the need for further intervention, the study reported a 10-year local retreatment rate of 33% and a radical treatment rate of 30% on an intention-to-treat basis. However, a post hoc per-protocol analysis showed that for patients adhering strictly to a protocol involving up to two focal ablative sessions, the rate of radical treatment was 8.9%. This suggests that many recurrences after an initial session can be managed with a second focal procedure rather than immediate radical surgery.

Implications for oncology nursing

For oncology nurses, these findings are critical for patient counseling. Nurses are often primary points of contact for patients managing the anxiety and "cancer patient insomnia" that can follow a diagnosis. Having data that supports a targeted treatment option is invaluable for shared decision-making.

The study suggests that even in higher-risk cases, focal therapy remains a viable option. Dr. Alexander Light, the study’s lead author, emphasized in a news release that many men with aggressive disease who were traditionally told focal therapy was not an option can now be considered for this approach.

Funding and policy considerations

The clinical implications of this research are already affecting healthcare policy in the UK. The government has announced £2.8 million in capital funding to expand focal therapy access. Also in the news release, professor Hashim Ahmed, a joint senior author, pointed out the current disparity in care: while up to 15,000 men per year could be eligible for focal therapy, only about 1,000 currently receive it due to limited local access.

The researchers hope these results will prompt an update to clinical guidelines to routinely offer focal therapy as a first-line choice. Future research will focus on developing prognostic risk calculators and improving the detection of locally recurrent disease through advanced imaging.

This study provides evidence that focal therapy using HIFU or cryotherapy is an effective treatment for localized prostate cancer over a 10-year period. As oncology moves toward more personalized care, focal therapy offers a path for patients to prioritize both survival and long-term functional health.

References

1. Light A, Peters M, Gopalakrishnan A, et al. Oncological outcomes following focal HIFU and cryotherapy for treatment of nonmetastatic prostate cancer in the United Kingdom: An updated analysis of 3477 patients from the prospective HEAT and ICE registries. Eur Urol. 2026;90(1). doi:10.1016/j.eururo.2026.05.007
2. Imperial College Healthcare NHS Trust. New study shows focal therapy effectively treats prostate cancer, keeping patients cancer free ten years after treatment. Published July 17, 2026. Accessed July 17, 2026. https://www.imperial.nhs.uk/about-us/news/new-study-shows-focal-therapy-treats-prostate-cancer